Abstract
For many years, the prevailing schema of alloreactivity made local immunosuppression illogical.1 The understanding was that a vascularized allograft was recognized by the host through peripheral sensitization. Host immune cells circulating through the graft were exposed to nonself histocompatibility antigens. Subsequent proliferation of responder cells occurred in the spleen or lymph nodes. The effector response was mediated by sensitized lymphoid cells returning to the graft and destroying cells bearing foreign histocompatibility antigens. Nonspecific immunosuppressive agents, such as azathioprine and steroids, interfered with proliferating cells in the spleen and other lymphoid depots. Given this schema, the value of immunosuppression at the graft site was doubtful.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ascher NL, Hoffman R, Hanto DW et al. Cellular events within the rejecting allograft. Transplantation 1983; 35: 193.
Hayry P Intragraft events in allograft destruction. Transplantation 1984; 38: 1.
Orosz CG, Bishop DK, Ferguson RM. In vivo mechanisms of alloreactivity. Transplantation 1989; 48: 818.
Stepkowski SM, Goto S, Ito T et al. Prolongation of heterotopic heart allograft survival by local delivery of continuous low-dose cyclosporine therapy. Transplantation 1989; 47: 17.
Ruers TJM, Buurman WA, Smits JFM et al. Local treatment of renal allografts, a promising way to reduce the dosage of immunosuppressive drugs. Transplantation 1986; 41: 156.
Ruers TJM, Daeman MJAP, Thijssen HHW et al. Sensitivity of graft rejection in rats to local immunosuppressive therapy. Transplantation 1988; 46: 820.
Gruber SA, Canafax DM, Cipolle RJ et al. Local immunosuppression of the vascularized graft. Surgery 1990; 107: 209.
Gruber SA. The case for local immunosuppression. Transplantation 1992; 54: 1.
Wang X, Berezniak R, Tafra L et al. Intraportal FK506 improves intrahepatic islet allograft survival. Transplant Proc 1991; 23: 3211.
Wang X, Alfrey EJ, Posselt A et al. Intraportal delivery of immunosuppression to intrahepatic islet allograft recipients. Transplant Int 1995; 8: 268.
Reckard CR, Barker CF. Transplantation of isolated pancreatic islets across strong and weak histocompatibility barriers. Transplant Proc 1973; 5: 761.
Naji A, Silvers WK, Plotkin SA et al. Successful islet transplantation in spontaneous diabetes. Surgery 1979; 86: 218.
Groth CG, ed. Pancreas and Islet Transplantation. Diabetes 1989; 38(suppl):1.
Theeuwes F, Yum SI. Principles of design and operation of generic osmotic pumps for the delivery of semisolid and liquid drug formulations. Ann Biomed Eng 1976; 4: 343.
Andersson A, Korsgren O, Jansson L. Intraportally transplanted pancreatic islets revascularized from hepatic arterial system. Diabetes 1989; 38 (suppl): 192.
Nash JR, Bell PRF. Islet transplantation - synergism between antilymphocyte and antimacrophage agents. J Surg Res 1984; 36: 154.
Gray DWR, Morris PJ. Developments in isolated pancreatic islet transplantation. Transplantation 1987; 43: 321.
Qian J, Kokudo S, Sato S et al. Tolerance induction of alloreactivity by portal venous inoculation with allogeneic cells followed by the injection of cyclophosphamide. Transplantation 1987; 43: 538.
Mattingly JA, Waksman BH. Immunologic suppression after oral administration of antigen. J Immunol 1978; 121: 1878.
Dubernard JM, Sutherland DER. International Handbook of Pancreas Transplantation. Dordrecht, the Netherlands: Kluwer Academic Publishers, 1989.
Van Der Vliet JA, Kaufman DB, Meloche RM et al. A simple method of canine pancreatic islet isolation and intrahepatic transplantation. J Surg Res 1989; 46: 126.
Alejandro R, Cutfield R, Shienvold FL et al. Successful long-term survival of pancreatic islet allografts in spontaneous or pancreatectomy-induced diabetes in dogs. Diabetes 1985; 34: 825.
Kamei T, Yasunami Y. Demonstration of donor specific unresponsiveness in rat islet allografts: importance of transplant site for induction by cyclosporin A and maintenance. Diabetologia 1989; 32: 779.
Reece-Smith H, Dutoit DF, McShane P et al. Prolonged survival of pancreatic islet allografts transplanted beneath the renal capsule. Transplantation 1981; 31: 305.
Ziegler MM, Reckard CR, Barker CF. Long term metabolic and immunological considerations in transplantation of pancreatic islets. J Surg Res 1974; 16: 575.
Edsbacker S, Andersson P, Lindberg C et al. Metabolic acetal splitting of budesonide. Drug Metab Disp 1987; 15: 403.
Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725.
Hahn HJ, Laube F, Lucke S et al. Toxic effects of cyclosporine on the endocrine pancreas of wistar rats. Transplantation 1986; 41: 44.
Peters DH, Fitton A, Plosker GL et al. Tacrolimus. Drugs 1993; 46: 746.
Jain AB, Ventakaramanan R, Cadoff E et al. Effect of hepatic dysfunction and T-tube clamping on FK506 pharmacokinetics and trough concentrations. Transplant Proc 1990; 22: 57.
Hirano Y, Fujihira S, Ohara K et al. Morphological and functional changes of islets of langerhans in FK506-treated rats. Transplantation 1992; 53: 889.
Ohara K, Billington R, James RW et al. Toxicologic evaluation of FK506. Transplant Proc 1990: 22: 83.
Venkataramanan R, Jain A, Cadoff E, at al. Pharmacokinetics of FK506. Transplant Proc 1990; 22: 52.
Tamura K, Kobayashi M, Hoshimoto K. A highly sensitive method to assay FK506 levels in plasma. Transplant Proc 1987; 19: 23.
Rights and permissions
Copyright information
© 1996 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Dafoe, D.C., Alfrey, E.J. (1996). Intraportal Delivery of Immunosuppressants to Intrahepatic Islet Allografts. In: Local Immunosuppression of Organ Transplants. Medical Intelligence Unit. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-22105-1_8
Download citation
DOI: https://doi.org/10.1007/978-3-662-22105-1_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-22107-5
Online ISBN: 978-3-662-22105-1
eBook Packages: Springer Book Archive